Ascendis Pharma A (ASND) EBT Margin (2014 - 2026)
Ascendis Pharma A (ASND) posted EBT Margin of 19.54% for Q1 2026, down 204.66% sequentially from 6.41% in Q4 2025, and up 7314.0% YoY from 0.26% in Q1 2025.
Powered by 
Analysis
Ascendis Pharma A (ASND) EBT Margin (2014 - 2026) Analysis & Trends
Ascendis Pharma A has reported EBT Margin for 13 years, with the latest figure at 19.54% in Q1 2026.
- Quarterly EBT Margin rose 7314.0% year-over-year to 19.54% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 16.15% (up 5124.0% YoY) and the FY2025 annual result came in at 29.53%, up 6245.0% from the prior year.
- EBT Margin fell to 19.54% in Q1 2026 per ASND's latest filing, from 6.41% in the prior quarter.
- Over five years, EBT Margin peaked at 6.41% in Q4 2025 and troughed at 1834.46% in Q1 2022.
- A 5-year average of 405.34% and a median of 169.76% in 2024 frame the typical range for EBT Margin.
- The widest YoY moves for EBT Margin: up 1183392 bps in 2022, down 75932 bps in 2022.
- Over 5 years, EBT Margin stood at 882.6% in 2022, then soared by 97 bps to 26.79% in 2023, then soared by 55 bps to 12.06% in 2024, then jumped by 47 bps to 6.41% in 2025, then sank by 205 bps to 19.54% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 19.54%, 6.41%, and 26.86% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Ascendis Pharma A | 16.39 Bn | 15.45 Bn | 362.22 Mn | 67.82% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 67.82% |
| Mar 31, 2026 | -19.54% |
| Dec 31, 2025 | -10.79% |
| Sep 30, 2025 | -26.86% |
| Jun 30, 2025 | -22.15% |
| Mar 31, 2025 | -92.68% |
| Dec 31, 2024 | -21.50% |
| Sep 30, 2024 | -169.76% |
| Jun 30, 2024 | -303.21% |
| Mar 31, 2024 | -134.03% |
| Dec 31, 2023 | -58.89% |
| Sep 30, 2023 | -336.38% |
| Jun 30, 2023 | -257.13% |
| Mar 31, 2023 | -326.35% |
| Dec 31, 2022 | -882.60% |
| Sep 30, 2022 | -1,106.10% |
| Jun 30, 2022 | -1,320.88% |
| Mar 31, 2022 | -1,834.46% |
| Dec 31, 2021 | -123.27% |
| Sep 30, 2021 | -7,218.60% |